Parenteral drug delivery; DNA origami builds a drug-delivery monorail;

> Pharma magazine takes in in-depth look at the commercialization of parenteral drug delivery systems based on microspheres, nanotechnology and implants. Article

> Inovio Pharmaceuticals unveils needle-free, contactless electroporation technology for DNA vaccine delivery Inovio release

> Lacerta Bio has a new client: A nanoparticle-based formulation and drug delivery company. More here

> Greystone Research Associates says needle-free injection (NFI) is attempting to shed its image as an out-of-the-mainstream drug delivery technique. The convergence of improved device designs, patient sentiment and new therapeutic applications is remaking NFI into an attractive technology being pursued by a number of major pharmaceutical companies. Release

> DNA origami builds a drug-delivery monorail. Yes, really. Read it

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.